Title : Upregulation of MKP-7 in response to rosiglitazone treatment ameliorates lipopolysaccharide-induced destabilization of SIRT1 by inactivating JNK.

Pub. Date : 2016 Dec

PMID : 27771463






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Upregulation of MKP-7 in response to rosiglitazone treatment ameliorates lipopolysaccharide-induced destabilization of SIRT1 by inactivating JNK. Rosiglitazone sirtuin 1 Mus musculus
2 Activation of PPARgamma by rosiglitazone, a specific ligand of PPARgamma, rescues LPS-induced destabilization of SIRT1, with a concomitant decrease in phosphorylation of residue Ser-46, which is targeted by JNK-1 to promote proteasome-mediated degradation of SIRT1. Rosiglitazone sirtuin 1 Mus musculus
3 Activation of PPARgamma by rosiglitazone, a specific ligand of PPARgamma, rescues LPS-induced destabilization of SIRT1, with a concomitant decrease in phosphorylation of residue Ser-46, which is targeted by JNK-1 to promote proteasome-mediated degradation of SIRT1. Rosiglitazone sirtuin 1 Mus musculus
4 The rosiglitazone-mediated increase in SIRT1 stability is accompanied by upregulation of mitogen-activated protein kinase phosphatase (MKP)-7, a JNK-specific phosphatase. Rosiglitazone sirtuin 1 Mus musculus
5 Furthermore, gain of MKP-7 function mimicked the effect of rosiglitazone on LPS-induced destabilization and ubiquitination of SIRT1. Rosiglitazone sirtuin 1 Mus musculus